In Depth Research on Global Antibody Drug Conjugate Market & Pipeline Insight2020

" Global Antibody Drug Conjugate Market & Pipeline Insight 2020" Report Highlight:

* Global Antibody Drug Conjugates Market Overview
* Mechanism of Antibody Drug Conjugates
* Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
* Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
* Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
* Antibody Drug Conjugates Patent Analysis
* Global Antibody Drug Conjugates Market Future Prospects

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Global-Antibody-Drug-Conjugate-Market-&-Pipeline-Insight2020.php

Table of Contents

1. Introduction to Antibody Drug Conjugates

2. Mechanism of Antibody Drug Conjugates

3. Global Antibody Drug Conjugates Market Overview
3.1 Current Market Scenario
3.2 Antibody Drug Conjugates Clinical Pipeline Overview

4. Global Antibody Drug Conjugates Market Dynamics
4.1 Favorable Market Parameters
4.1.1 Research & Development
4.1.2 Strong Clinical Pipeline
4.1.3 Increasing Disease Incidences
4.1.4 Demand for Better Therapeutics
4.2 Commercialization Challenges

5. Global Antibody Drug Conjugates Market Future Prospects

6. Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-II/III
6.7 Phase-III

7. Marketed Antibody Drug Conjugates Clinical Insight
7.1 Abatacept (Orencia®, Orencia® IV & Orencia® SC)
7.2 Belatacept (Nulojix®)
7.3 Brentuximab Vedotin (Adcetris®)
7.4 Gemtuzumab Ozogamicin (Mylotarg®)
7.5 Ibritumomab Tiuxetan (Zevalin® & Zevamab®)
7.6 Mifamurtide (Junovan™ & Mepact®)
7.7 Satumomab (OncoScint CR/OV®)
7.8 Trastuzumab Emtansine (Kadcyla®)

8. Discontinued & Suspended Antibody Drug Conjugates Clinical Insight
8.1 No Development Reported
8.2 Discontinued
8.3 Market Withdrawal
8.4 Suspended

9. Competitive Landscape
9.1 AbbVie
9.2 AbGenomics Corporation
9.3 Astella Pharma
9.4 AREVA Med
9.5 AREVA Med
9.6 Biogen Idec
9.7 Biotest
9.8 Bristol Myers Squibb
9.9 Celldex Therapeutics Inc
9.10 Helix BioPharma
9.11 IBC Pharmaceuticals
9.12 ImmunoGen
9.13 Immunomedics
9.14 Merck
9.15 Merrimack Pharmaceuticals
9.16 Millennium
9.17 Nordic Nanovector
9.18 Novartis
9.19 PDL BioPharma
9.20 Progenics Pharmaceuticals
9.21 Roche
9.22 Seattle Genetics
9.23 Stem CentRx
9.24 UCB
9.25 Viventia Biotechnologies
9.26 Xenikos

Figure 1-1: Properties of Antibody Drug Conjugates
Figure 1-2: Components of Antibody Drug Conjugates
Figure 1-3: Types of Linkers
Figure 1-4: Limitations of Antibody Drug Conjugates
Figure 2-1: Mechanism of Brentuximab Vedotin
Figure 2-2: Mechanism of Trastuzumab Emtansine
Figure 3-1: Global Antibody Drug Conjugate Market (US$ Billion), 2014-2020
Figure 3-2:Global Adcetris Sales (Million US$), 2016-2020
Figure 3-3: Global Kadcyla Sales (Million US$), 2016-2020
Figure 3-4: Antibody Drug Conjugates Pipeline by Phase (%), 2015
Figure 3-5: Antibody Drug Conjugates Pipeline by Phase (Number), 2015
Figure 3-6: No Development Reported Antibody Drug Conjugates Pipeline by Phase (%), 2015
Figure 3-7: No Development Reported Antibody Drug Conjugates Pipeline by Phase (Number), 2015
Figure 3-8: Discontinued Antibody Drug Conjugates Pipeline by Phase (%), 2015
Figure 3-9: Discontinued Antibody Drug Conjugates Pipeline by Phase (Number), 2015
Figure 3-10: Suspended Antibody Drug Conjugates Pipeline by Phase (%), 2015
Figure 3-11: Suspended Antibody Drug Conjugates Pipeline by Phase (Number), 2015
Figure 4-1: Antibody Drug Conjugates Market Favorable Parameters
Figure 9-1:AbGenomics-Clinical Pipeline
Figure 9-2: Celldex Clinical Pipeline
Figure 9-3: Merck Clinical Pipeline
Figure 9-4: Merrimack Clinical Pipeline
Figure 9-5: Millennium Clinical Pipeline
Figure 9-6: Novartis Clinical Pipeline
Figure 9-7: Progenics Clinical Pipeline
Figure 9-8: Roche Clinical Pipeline
Figure 9-9: Seattle Genetics Clinical Pipeline
Figure 9-10: Viventia Clinical Pipepline


List of Tables

Table 2-1: Antibody Drug Conjugates under Development
Table 3-1: Antibody Drug Conjugates Approved Till Date, 2015
Table 3-2: Drugs for Treatment of HER2-Positive Breast Cancer

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.